Pipeline — registered trials by phase
Clinical Study to Evaluate the RxSight Light Adjustable Lens With the Light Delivery Device in Subjects With Preoperative Corneal Astigmatism
— · Cataract · Completed · est. 2019-07-01
Single Center Exploratory Study To Evaluate The Use Of The RxSight Light Adjustable Lens (LAL) And The Light Delivery Device (LDD) To Improve Visual Outcomes
— · Aphakia, Cataract · Completed · est. 2022-10-01
Exploratory Study to Evaluate Uncorrected Distance Vision and Quality of Vision After Light Treatments of an Implanted RxSight Light Adjustable Lens (RXLAL) With The Light Delivery Device (LDD) in Subjects With Preoperative Corneal Astigmatism
— · Aphakia, Cataract · Completed · est. 2019-04-15
Clinical Study to Evaluate the Safety and Effectiveness of the RxSight Light Adjustable Lens (LAL) in Subjects With Prior Corneal Refractive Surgery
— · Aphakia, Cataract · Completed · est. 2020-04-01
Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes
— · Aphakia, Cataract · Completed · est. 2020-03-01
Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study
— · Aphakia Cataract · Enrolling By Invitation · est. 2026-09
A Clinical Study to Evaluate The Safety and Effectiveness of Performing 0.50 Diopter Astigmatism Correction on the Commercially Available RxSight Light Adjustable Lens (LAL)
— · Aphakia, Cataract · Completed · est. 2020-03-01
RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study
— · Aphakia, Cataract · Completed · est. 2024-09-11
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where RxSight is lead sponsor; 8 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- SC TO-I/A2026-09-08SC TO-I/A
- SC TO-I/A2026-08-25SC TO-I/A
- SCHEDULE 13G2026-08-19SCHEDULE 13G
- SC TO-I2026-08-10SC TO-I
- 10-Q2026-08-05Quarterly report
- 8-K2026-08-05Current report (material event)
- SCHEDULE 13G/A2026-08-04SCHEDULE 13G/A
- S-82026-07-23Employee stock plan
- SCHEDULE 13G2026-07-17SCHEDULE 13G
- 8-K2026-07-15Current report (material event)
- 8-K2026-07-06Current report (material event)
- 8-K2026-07-06Current report (material event)
- 8-K2026-06-16Current report (material event)
- SD2026-05-29SD
- SCHEDULE 13G/A2026-05-13SCHEDULE 13G/A
- 10-Q2026-05-06Quarterly report
- 8-K2026-05-06Current report (material event)
- ARS2026-04-28Annual report to holders
- DEFA14A2026-04-28DEFA14A
- DEF 14A2026-04-28Proxy statement
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 8-K/A2026-03-19Current report (amended)
- EFFECT2026-02-26EFFECT
- POS AM2026-02-25POS AM
- S-82026-02-25Employee stock plan
- 10-K2026-02-25Annual report
- 8-K2026-02-25Current report (material event)
- POSASR2026-02-13POSASR
- SCHEDULE 13G2026-02-03SCHEDULE 13G
- 8-K2026-01-12Current report (material event)
- 8-K2025-12-23Current report (material event)
- 8-K2025-12-22Current report (material event)
- 8-K2025-12-19Current report (material event)
- SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
- SCHEDULE 13G/A2025-11-12SCHEDULE 13G/A
- 10-Q2025-11-05Quarterly report
- 8-K2025-11-05Current report (material event)
- SCHEDULE 13G/A2025-11-04SCHEDULE 13G/A
- SCHEDULE 13G/A2025-10-17SCHEDULE 13G/A
- 8-K/A2025-08-15Current report (amended)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.